Ibrutinib for the Treatment of Bing-Neel Syndrome

Gilad Itchaki, MD1, Jonas Paludo, MD2, Maria Lia Palomba, MD3, Marzia Varettoni, MD4, Dipali Talaulikar, PhD, FRACP5, Julio C Chavez, MD6, Christian Buske, MD7, Alessandra Tedeschi, MD8, David Simpson, MBChB, FRACP8, Constantine S Tam, MBBS, MD, FRACP10, Sammy Issa, FRACP11, Stephen M Ansell, MD, PhD12, Steven P Treon, MD, PhD, FRCP13 and Jorge J Castillo, MD1

1Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA, USA 2Mayo Clinic, Rochester, MN, USA 3Memorial Sloan Kettering Cancer Center, New York, NY, USA 4Fondazione IRCCS Policlinico San Matteo, Pavia, Italy 5The Canberra Hospital, Red Hill, Australia 6Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA 7Comprehensive Cancer Center Ulm, Ulm, Germany 8Niguarda Cancer Center, Milan, Italy 9North Shore Hospital, Auckland, New Zealand 10Peter MacCallum Institute, Melbourne, Australia 11Middlemore Hospital, Auckland, New Zealand

Background

- Bing-Neel syndrome (BNS) is a rare complication of Waldenstrom macroglobulinemia (WM), in which WM cells gain access to the CNS causing neurological deficits1.
- Treatment options in patients with BNS are limited
- Ibrutinib, an oral BTK-inhibitor, and the only approved therapy in WM, can penetrate into the CNS2, but data on BNS is lacking.

Aim

To evaluate the efficacy of ibrutinib in patients with BNS

Methods

- A multicenter retrospective study
- Diagnosis of BNS was established in pts with WM by radiological and/or cytological evidence of CNS involvement by WM
- Ibrutinib was given at 420-560 mg PO qd until disease progression or intolerable toxicity
- Response was assessed based on recently published criteria3
- Events were defined as death from any cause, progression of disease, and stopping ibrutinib from any reason. Time-to-events were estimated using the Kaplan-Meier method.

Results – Patients Characteristics

24 pts are reported

WM Dx: median age 60 years (38-76); 58% ♂

- Median time to BNS Dx was 4 years (0-27)
- Median lines of therapy was 1 (0-7), including anti-CD20 antibodies (n=15), alkylators (13), nucleoside analogues (8), proteasome inhibitors (3), immunomodulators (2), and autologous transplant (1).
- 9 pts (38%) were untreated prior to BNS

BNS Dx: median age 65 years (38-80)

- BNS symptoms @ presentation were cognitive deficits (n=10), sensory deficits (8), ataxia/falls (8), motor deficits (6), headache (5), and seizures (5).
- MRI findings demonstrated leptomeningeal enhancement (n=16) and/or brain masses (5), and were normal in 4.
- CSF flow cytometry was positive in 19 pts (79%)
- Brain biopsies were performed in 5 pts (21%)
- Tissue not obtained in 1 pt with pathological MRI
- Median serum IgM (n=20) prior to ibrutinib initiation was 1,294 mg/dl (125-5,938); 2 pts secreted IgG
- Median hemoglobin level was 11.9 g/dl (7.7-15.2)

- Median lines of BNS therapy prior to ibrutinib was 1 (0-5), including i.th. chemotherapy (n=9), high-dose methotrexate (6), bendamustine (3) and radiation therapy (3).
- Ibrutinib was the 1st BNS therapy in 7 pts (29%)

- Median time to BNS Dx was 4 years (0-27)
- Median lines of therapy was 1 (0-7), including anti-CD20 antibodies (n=15), alkylators (13), nucleoside analogues (8), proteasome inhibitors (3), immunomodulators (2), and autologous transplant (1).
- 9 pts (38%) were untreated prior to BNS

Results – Response Assessment

- Median follow-up was 13 months (95% CI 8-21 months)
- At best response –
  - Median serum IgM and hemoglobin levels were 340 mg/dl (82-3,330) and 14.6 g/dl (9.2-16.0).
  - Based on consensus BNS response criteria, CR was attained in 2 pts (8%), PR in 14 (58%) and clinical improvement in 3 (13%).
  - 5 pts stopped ibrutinib: 3 due to BNS progression, 1 due to grade 3 muscle cramps and 1 due to arrhythmia.
  - 3 patients have died - 2 from infection and 1 from BNS progression.
  - The median event-free survival (EFS) from ibrutinib initiation was not yet reached.

Results – Patients Characteristics

Ibrutinib Rx:

- 10 pts (42%) received ibrutinib 560 mg qd and 14 (58%) 420 mg

Results – Response Assessment

- 1-year & 2-year EFS rates were 71% (95% CI 46-86%) and 52% (23-75%).
- 2-year OS rate was 80%

Conclusion

Ibrutinib is a safe and effective treatment option for patients with BNS

References


Corresponding author: Jorge_Castillo@dfci.harvard.edu

There are no relevant relationships to disclose. Please see attached COI for details.